Cargando…
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the normal development of several endoderm-derived organs, including the prostate gland(1,2). FOXA1 is frequently mutated in the hormone-receptor driven prostate, breast, bladder, and salivary gland tumors(3–8). However,...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661908/ https://www.ncbi.nlm.nih.gov/pubmed/31243372 http://dx.doi.org/10.1038/s41586-019-1347-4 |
_version_ | 1783439551091441664 |
---|---|
author | Parolia, Abhijit Cieslik, Marcin Chu, Shih-Chun Xiao, Lanbo Ouchi, Takahiro Zhang, Yuping Wang, Xiaoju Vats, Pankaj Cao, Xuhong Pitchiaya, Sethuramasundaram Su, Fengyun Wang, Rui Feng, Felix Y. Wu, Yi-Mi Lonigro, Robert J. Robinson, Dan R. Chinnaiyan, Arul M. |
author_facet | Parolia, Abhijit Cieslik, Marcin Chu, Shih-Chun Xiao, Lanbo Ouchi, Takahiro Zhang, Yuping Wang, Xiaoju Vats, Pankaj Cao, Xuhong Pitchiaya, Sethuramasundaram Su, Fengyun Wang, Rui Feng, Felix Y. Wu, Yi-Mi Lonigro, Robert J. Robinson, Dan R. Chinnaiyan, Arul M. |
author_sort | Parolia, Abhijit |
collection | PubMed |
description | Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the normal development of several endoderm-derived organs, including the prostate gland(1,2). FOXA1 is frequently mutated in the hormone-receptor driven prostate, breast, bladder, and salivary gland tumors(3–8). However, how FOXA1 alterations affect cancer development is unclear, with FOXA1 previously ascribed both tumor suppressive(9–11) and oncogenic(12–14) roles. Here we assemble an aggregate cohort of 1546 prostate cancers (PCa) and show that FOXA1 alterations fall into three distinct structural classes that diverge in clinical incidence and genetic co-alteration profiles, with a collective prevalence of 35%. Class1 activating mutations originate in early PCa without ETS/SPOP alterations, selectively recur within the Wing2-region of the DNA-binding Forkhead domain (FKHD), enable enhanced chromatin mobility and binding frequency, and strongly transactivate a luminal androgen receptor (AR) program of prostate oncogenesis. By contrast, class2 activating mutations are acquired in metastatic PCa, truncate the C-terminal domain of FOXA1, enable dominant chromatin binding by increasing DNA affinity, and through TLE3 inactivation promote WNT-pathway driven metastasis. Finally, class3 genomic rearrangements are enriched in metastatic PCa, comprise of duplications and translocations within the FOXA1 locus, and structurally reposition a conserved regulatory element, herein denoted FOXA1 Mastermind (FOXMIND), to drive overexpression of FOXA1 or other oncogenes. Our study reaffirms the central role of FOXA1 in mediating AR-driven oncogenesis, and provides mechanistic insights into how different classes of FOXA1 alterations uniquely promote PCa initiation and/or metastatic progression. Furthermore, these results have direct implications in understanding the pathobiology of other hormone-receptor driven cancers and rationalize therapeutic co-targeting of FOXA1 activity. |
format | Online Article Text |
id | pubmed-6661908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-66619082019-12-26 Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer Parolia, Abhijit Cieslik, Marcin Chu, Shih-Chun Xiao, Lanbo Ouchi, Takahiro Zhang, Yuping Wang, Xiaoju Vats, Pankaj Cao, Xuhong Pitchiaya, Sethuramasundaram Su, Fengyun Wang, Rui Feng, Felix Y. Wu, Yi-Mi Lonigro, Robert J. Robinson, Dan R. Chinnaiyan, Arul M. Nature Article Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the normal development of several endoderm-derived organs, including the prostate gland(1,2). FOXA1 is frequently mutated in the hormone-receptor driven prostate, breast, bladder, and salivary gland tumors(3–8). However, how FOXA1 alterations affect cancer development is unclear, with FOXA1 previously ascribed both tumor suppressive(9–11) and oncogenic(12–14) roles. Here we assemble an aggregate cohort of 1546 prostate cancers (PCa) and show that FOXA1 alterations fall into three distinct structural classes that diverge in clinical incidence and genetic co-alteration profiles, with a collective prevalence of 35%. Class1 activating mutations originate in early PCa without ETS/SPOP alterations, selectively recur within the Wing2-region of the DNA-binding Forkhead domain (FKHD), enable enhanced chromatin mobility and binding frequency, and strongly transactivate a luminal androgen receptor (AR) program of prostate oncogenesis. By contrast, class2 activating mutations are acquired in metastatic PCa, truncate the C-terminal domain of FOXA1, enable dominant chromatin binding by increasing DNA affinity, and through TLE3 inactivation promote WNT-pathway driven metastasis. Finally, class3 genomic rearrangements are enriched in metastatic PCa, comprise of duplications and translocations within the FOXA1 locus, and structurally reposition a conserved regulatory element, herein denoted FOXA1 Mastermind (FOXMIND), to drive overexpression of FOXA1 or other oncogenes. Our study reaffirms the central role of FOXA1 in mediating AR-driven oncogenesis, and provides mechanistic insights into how different classes of FOXA1 alterations uniquely promote PCa initiation and/or metastatic progression. Furthermore, these results have direct implications in understanding the pathobiology of other hormone-receptor driven cancers and rationalize therapeutic co-targeting of FOXA1 activity. 2019-06-26 2019-07 /pmc/articles/PMC6661908/ /pubmed/31243372 http://dx.doi.org/10.1038/s41586-019-1347-4 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Parolia, Abhijit Cieslik, Marcin Chu, Shih-Chun Xiao, Lanbo Ouchi, Takahiro Zhang, Yuping Wang, Xiaoju Vats, Pankaj Cao, Xuhong Pitchiaya, Sethuramasundaram Su, Fengyun Wang, Rui Feng, Felix Y. Wu, Yi-Mi Lonigro, Robert J. Robinson, Dan R. Chinnaiyan, Arul M. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer |
title | Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer |
title_full | Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer |
title_fullStr | Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer |
title_full_unstemmed | Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer |
title_short | Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer |
title_sort | distinct structural classes of activating foxa1 alterations in advanced prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661908/ https://www.ncbi.nlm.nih.gov/pubmed/31243372 http://dx.doi.org/10.1038/s41586-019-1347-4 |
work_keys_str_mv | AT paroliaabhijit distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT cieslikmarcin distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT chushihchun distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT xiaolanbo distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT ouchitakahiro distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT zhangyuping distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT wangxiaoju distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT vatspankaj distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT caoxuhong distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT pitchiayasethuramasundaram distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT sufengyun distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT wangrui distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT fengfelixy distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT wuyimi distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT lonigrorobertj distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT robinsondanr distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer AT chinnaiyanarulm distinctstructuralclassesofactivatingfoxa1alterationsinadvancedprostatecancer |